Adcomm backs use of minimal residual disease in multiple myeloma accelerated approvals

 A new oncology drug endpoint, based on what’s known as minimal residual disease, gained the backing of FDA advisors, potentially opening the door to new trial designs for blood cancer drugs.

An FDA advisory committee voted unanimously on Friday that evidence supports a new intermediate endpoint for accelerated approvals in multiple myeloma.

https://endpts.com/adcomm-backs-use-of-minimal-residual-disease-in-multiple-myeloma-accelerated-approvals/